End-to-end platform for DUB drug discovery and development
Interested in discounted access to DUBprofiler – Check out our latest September Offer – https://www.ubiquigent.com/posts/dubprofiler-september-offer-2023

Our specialised drug discovery platform and long-standing expertise is empowering scientists to develop DUB inhibitors, DUB-targeting PROTACs, and DUBTACs into exciting new medicines

Ubiquigent™ has the assays, expertise, and capabilities to drive forward every step in the drug discovery workflow, from DUB target identification and validation to the identification and characterisation of novel DUB targeting compounds in vitro, in cells and in tissues.

Driving DUB drug discovery and development

As pioneers in the rapidly emerging deubiquitinase (DUB) space, Ubiquigent™ is uniquely positioned to drive forward the discovery and development of novel DUB modulators as powerful new therapeutics for areas of high unmet need.
Founded 13 years ago, Ubiquigent has cultivated an unrivalled track record and comprehensive range of specialist services focused on the exploitation of DUBs and the ubiquitin-proteasome system (UPS). As such, we are the partner chosen by many leading industry and academic organisations for their drug discovery programmes spanning the development of DUB inhibitors and modulators in the fields of protein degradation, stabilisation, and homeostasis.

Alongside the delivery of specialist services to customers, we have an internal pipeline of drug discovery programmes and are developing a strong IP portfolio encompassing DUB inhibitors, DUB-targeting Proteolysis Targeting Chimeras (PROTACs) and Deubiquitinase-Targeting Chimeras (DUBTACs), providing potential new starting points for client discovery programmes through partnerships and out-licensing agreements.

Ubiquigent benefits from high calibre backing, including from IP Group PLC and Scottish Enterprise. Based in a state-of-the-art facility located in Dundee, Scotland, we sit at the centre of highly relevant additional scientific expertise and capabilities.